Portfolio PR – Sound Bioventures

All Fund articles Fund PR Portfolio articles Portfolio PR

Altay Therapeutics Closes $37 Million Series A Financing to Advance First Oral DUX4 Inhibitor for FSHD into the Clinic

2026.10.152026.10.15 / DX5057 is an orally administered small molecule designed to inhibit DUX4 transcriptional activity and expression of its targeted proteins Clinical program will explore DUX4-related biomarkers and ...

AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness

2026.09.302026.09.30 / Financing co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing investors Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, ...

Breye - Portfolio Company

Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational Medicine

2026.09.242026.09.24 / Oral treatment danegaptide represents “a potential paradigm shift” toward earlier, non-invasive treatment of Non-Proliferative Diabetic Retinopathy (NPDR), say authors Study “provides compelling ...

VarmX recognised with two prestigious industry award nominations

2026.09.222026.09.22 / Nominated for the 2026 Prix Galien USA “Best Startup” Award, and shortlisted with partner CSL for “Deal of the Year” at the 2026 European Lifestars Awards Leiden, The Netherlands, 15 Septemb ...

Teitur Trophics announces successful results from Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34

2026.09.102026.09.10 / · Study shows TT-P34 is safe and well tolerated in healthy volunteers and patients with early-stage Parkinson’s disease (PD), with pharmacokinetics confirming robust CNS exposure · Early ...

Cytospire Therapeutics Appoints Highly Experienced Immuno-Oncology Leader, Sumeet Ambarkhane, M.D., as Chief Medical Officer

2026.09.082026.09.08 / Dr Ambarkhane brings proven 20+ year track record advancing innovative cancer therapies through clinical development and regulatory approval Appointment strengthens Cytospire's executive leadersh ...

VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX-C001 in urgent surgery

2026.08.202026.08.20 / • First participant enrolled: EquilibriX-S (NCT07288489), a landmark registrational Phase 3 study of VMX-C001 vs usual pharmacologic care in patients taking FXa inhibitors who require an urgent surge ...

ARTHEx biotech

ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)

2026.07.232026.07.23 / New data show systemic delivery of antimiR-23b developed on Arthex BOOST-ON™ platform reaches the brain, corrects disease biology, and improves behavior—highlighting potential to address CNS manifest ...

Theolytics

Theolytics Relocates to State-of-the-Art Facility at ARC Oxford to Drive Development of THEO-260 and Other Novel Oncolytic Immunotherapies

2026.07.162026.07.16 / Oxford UK, July 14th, 2026. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, announces that it has relocated to new, state-of-the-art facilitie ...

Simon Mølgaard Named Rising Star in Danish Biotech

2026.06.292026.06.29 / We are proud to congratulate Simon Mølgaard, CEO of our portfolio company Teitur Trophics, on being awarded the Rising Star in Danish Biotech at the Biotech Spring Gala — with the recognition display ...

AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet

2026.06.252026.06.29 / Favourable safety profile in marked contrast to traditional inotropic therapeutics AC01 showed rapid and sustained improvements in cardiac output, structure and function STOCKHOLM, Sweden, [D ...

ARTHEx biotech

ARTHEx Biotech Delivers Multiple Presentations at IDMC-15 Highlighting Clinical Progress of ATX-01 and Mechanistic Insights for Myotonic Dystrophy Type 1 (DM1) and 2 (DM2)

2026.05.272026.05.27 / Valencia, Spain, May 27, 2026 — Arthex Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced multiple presentations at the ...